Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

284
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
284
Introduction to Fibroblasts01:09

Introduction to Fibroblasts

3.0K
Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
3.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

JAK2<sup>V617F</sup>-positive clonal hematopoiesis in germline BRCA1 versus BRCA2 mutation carriers.

Leukemia·2026
Same author

TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis.

Blood·2026
Same author

Type I interferon-activated NK cells control polycythemia vera in vivo.

Blood·2026
Same author

The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.

Blood advances·2026
Same author

Frequent and clinically relevant germline DNA repair gene variants in young and familial myeloproliferative neoplasms.

Blood cancer journal·2026
Same author

NLRP3-induced systemic inflammation controls the development of JAK2V617F mutant myeloproliferative neoplasms.

Nature communications·2025

Related Experiment Video

Updated: Jun 5, 2025

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.7K

Novel approaches in myelofibrosis.

Steffen Koschmieder1,2

  • 1Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty RWTH Aachen University Aachen Germany.

Hemasphere
|December 13, 2024
PubMed
Summary

Myelofibrosis treatments are evolving beyond current therapies. New drugs and clinical trials aim to improve long-term outcomes by targeting specific mutations and pathways for better disease control.

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.6K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.0K

Related Experiment Videos

Last Updated: Jun 5, 2025

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.7K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.6K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.0K

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Myelofibrosis (MF) is a serious clonal myeloid neoplasm with significant morbidity and mortality.
  • Current treatments for MF include risk-stratified approaches, with stem cell transplantation for high-risk patients and JAK inhibitors for symptomatic lower-risk patients.
  • Existing therapies lack durable complete remission rates, necessitating novel treatment strategies for improved long-term patient outcomes.

Purpose of the Study:

  • To review current and emerging preclinical and clinical therapeutic approaches for myelofibrosis.
  • To highlight novel monotherapies and drug combinations targeting various intracellular and extracellular pathways.
  • To discuss innovative strategies including mutation-specific inhibitors and antifibrotic agents.

Main Methods:

  • Review of preclinical studies and ongoing clinical trials in myelofibrosis therapy.
  • Analysis of novel therapeutic targets including JAK-STAT, PI3-Kinase, TP53, and S100A8/A9 pathways.
  • Exploration of immunotherapeutic approaches and antifibrotic strategies.

Main Results:

  • Emerging therapies target diverse pathways such as transcription, nuclear export, and survival signaling.
  • Preclinical research is exploring mutation-specific inhibitors (e.g., JAK2V617F) and DNA repair pathway inhibitors.
  • New clinical trial endpoints focus on disease modification and overall survival, moving beyond symptom improvement.

Conclusions:

  • Novel therapeutic strategies, including drug combinations and targeted agents, show promise for MF management.
  • Advancements in understanding MF pathogenesis are driving the development of innovative treatments.
  • The next generation of clinical trials is expected to significantly improve long-term disease control and patient outcomes in myelofibrosis.